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A B S T R A C T
The frequency of psychiatric disorders (PD) in a homogeneous series of patients with temporal lobe
epilepsy with mesial temporal sclerosis (TLE-MTS) compared to patients with juvenile myoclonic
epilepsy (JME) was evaluated, aiming to determine the frequency of PD and possible differences in
psychiatric diagnoses between these two epileptic syndromes. Data from 248 patients with refractory
TLE-MTS and from 124 JME patients were reviewed and compared. There was a high prevalence of PD in
both groups of epilepsy patients, present in 100 TLE-MTS (41%) and in 58 JME patients (46.7%). Mood
(23.7%), anxiety (13.7%) and psychotic (11.6%) disorders were the most frequent diagnoses in TLE-MTS
group, while mood and anxiety disorders (25% and 21%, respectively) were the most common PD among
JME. Psychoseswere signiﬁcantly associatedwith TLE-MTS (p = 0.01). These observations are concordant
with our previous study, reforcing the existence of a possible anatomic correlation of PD and brain
structures involved in both epilepsy syndromes.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The association between epilepsy and psychiatric disorders
(PD) has been recognized for centuries and has become a matter of
interest, with important studies emphasizing these aspects.1–8
Available data support an increased risk for psychiatric comorbid-
ity in epilepsy patients, indicating that it occurs in 20–40% of this
population, being even more frequent in patients with refractory
seizures, in which this prevalence can be as high as 70%.2 Although
studies have highlighted temporal lobe epilepsy (TLE) patients to
be at an increased risk for PD when compared to those with
extratemporal or primary generalized epilepsies, this was not
conﬁrmed by other studies.9–13 There is also a lack of data
regarding the frequency of PD in speciﬁc etiologies of TLE such as
mesial temporal sclerosis (TLE-MTS), a condition that compro-
mises mainly structures of the limbic system, particularly the
hippocampus and the amygdala. In addition, few studies had
performed adequate controlled analyses using well-established
diagnostic instruments for PD.2,8,13 Besides, they have concentrat-
ed mainly in patients with TLE,5–8 and a lack of data regarding the
prevalence of PD in other epileptic syndromes still exists.8,13* Corresponding author at: Rua Botucatu, 740, Vila Clementino, Sa˜o Paulo, SP,
CEP: 04023-900, Brazil. Tel.: +55 11 5539 1792; fax: +55 11 5549 3819.
E-mail address: ﬁlho.gerardo@gmail.com (G.M. de Arau´jo Filho).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.007Several investigators have reported a high prevalence of PD
among patients with primary generalized epilepsies (PGE).14–19
Recent studies have observed that up to one-third of patients with
adult-onset PGE are diagnosed and treated for PD,16–19 and a high
frequency of mood and anxiety disorders, as well as mild to
moderate personality disorders have been reported.16–18 Juvenile
myoclonic epilepsy (JME) is a well deﬁned primary generalized
epileptic syndrome that comprises 5–11% of patients with
epilepsy, characterized by myoclonic jerks and generalized
tonic-clonic seizures (GTCS) and typical ﬁndings of generalized
4–6 Hz spike and wave or poly-spike and wave activity maximum
in frontocentral regions in electroencefalogram (EEG).2 In this
syndrome high rates of PD, particularly anxiety, mood and mild to
moderate personality disorders have been described14–18 as well
as frontal lobe dysfunctions.2,20,21
The frequency of PD in a group of 170 TLE-MTS and 100 JMEwas
performed in a previous study,19 and no signiﬁcant differences in
the frequency and number of psychiatric diagnoses were observed
when both groups were compared. In order to conﬁrm those
previous ﬁndings, we evaluated the frequency of axis I disorders in
a homogeneous series of 248 patients with refractory TLE-MTS and
in 124 with JME, aiming to investigate differences in types of PD in
each group and possible correlations to clinical and physiopatho-
logical variables, such as duration of the disease, family history of
epilepsy, and laterality of MTS. We focused our attention on the
analysis of the importance of the type of epileptic syndrome (focalvier Ltd. All rights reserved.
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ing possible anatomic correlations between the epileptic syn-
drome and its psychiatric comorbidity.1,14
2. Methods
2.1. Subjects
All patients were followed-up in the outpatient’s clinic of a
tertiary center (Epilepsy Section of the Universidade Federal de Sa˜o
Paulo, Sa˜o Paulo, Brazil), from July 2005 to July 2010. After previous
consent, 248 with refractory TLE-MTS and 124 patients with JME
were included. The inclusion criteria were the presence of
electroclinical diagnosis of JME or TLE based on ILAE classiﬁca-
tion22 and having been treated in our unit for at least 6 months. All
TLE patients also had clear MRI ﬁndings consistent with unilateral
or bilateral MTS and concordant interictal and ictal EEG data. JME
patients had typical EEG showing generalized 3–6 Hz spike and
wave or poly-spike and wave activity maximum in frontocentral
regions. Exclusion criteria were clinical illnesses besides epilepsy
and antihistamine administration or alcohol consumption within
72 h prior to the evaluation. Caffeine or nicotine use on the day of
testing, different from that usually taken, was also considered
exclusion criteria.
2.2. Procedures
Patients with TLE underwent 2–6 days of continuous video-EEG
monitoringwith 32-channel EEG recording, with electrodes placed
according to 10-10 system on the temporal lobe, including
sphenoidal electrodes. MTS was deﬁned if atrophy, an increased
T2-weighted signal, a decreased T1-weighted signal, and disrupted
internal structure of the hippocampus were present accompanied
by atrophy of the amygdala and/or temporal pole signal alteration
on visual inspection of MRI pictures. The epileptogenic zone was
determined by predominantly ipsilateral interictal epileptiform
abnormalities (80% cutoff) and seizure onset recorded during
prolonged video-EEG monitoring. TLE was considered resistant to
medical treatment when seizures persisted after the utilization of
at least two ﬁrst line medications for partial seizures at highest
tolerated doses.
Since most of JME patients continued presenting occasional
absences and myoclonic seizures, making seizure counting
difﬁcult, a good response to treatment was considered the control
of GTCS for at least 1 year. For statistical analisys, JME patients
were divided into three groups, according to the presence of
seizures: myoclonic plus GTCS, myoclonic plus absence and
myoclonic plus absence plus GTCS.
2.3. Psychiatric evaluation
Clinical and socio-demographic data from patients were
reviewed. All patients were evaluated by the same psychiatrist
(GMAF) through the structured questionnaire Schedule ClinicalTable 1
Clinical and demographic data of patients with mesial temporal sclerosis and juvenile
Clinical/demographic data Mesial temporal sclerosis
Age (mean SD) 37.411.0
Gender (% females) 138 (55.6)
Age at epilepsy onset (mean SD) 11.610.2
Duration of epilepsy (mean SD) 25.711.1
Family history of epilepsy (%) 71 (28.6)
Patients with psychiatric disorders (axis I) (%) 100 (41)
Total of psychiatric comorbidities (axis I) 134
* p<0.05.Interview for DSM-IV, axis I (SCID I), which is a diagnostic
instrument based on DSM-IV (Diagnostical and Statistical Manual
of Mental Disorders),23 having been internationally used to
evaluate the prevalence of PD. For statistical comparisons, since
each patient could have had more than one axis I psychiatric
diagnosis, the number of patients diagnosed and all comorbid PD
found in each group were both considered and were analysed
separately. The temporality between epileptic seizures and
psychotic symptomatologywas the utilized criteria to differentiate
postictal psychosis (PIP) from interictal psychosis (IIP).24
2.4. Statistics
Statistical analyses were performed with SPSS 10.0 software.
Some socio-demographic characteristics were presented as one-
sample proportions and with conﬁdence intervals. The chi-square
(x2) was used to calculate themajority of differences between both
groups. Fisher’s exact test, the generalization of Fisher’s exact test,
Z test and Student’s t test for unequal variances were applied both
to calculate the differences between the groups and the relation-
ship between the group of patients and socio-demographic and
epilepsy characteristic variables. p value of <0.05 was considered
signiﬁcant.
3. Results
The TLE-MTS and JME groups were paired according to age,
gender, duration of epilepsy and age at epilepsy onset. MTS
occurred more frequently on left side (146 patients; 58.8%),
followed by right (86; 34.6%) and by 16 in which this lesion was
seen bilaterally (6.6%). Seventy-nine patients had a history of
initial precipitant injury (IPI), febrile seizures being the most
frequent (45 cases; 56.9%). There were also 24 cases of head
trauma, 7 of meningoencephalitis and 3 of perinatal hypoxia. The
majority of MTS patients (191; 77%) had been in use of association
of two or more AED. Carbamazepine (CBZ), in monotherapy or in
association with other drugs, was the most frequent AED (162
patients; 65.3%), followed by phenobarbital (PB) (74; 29.8%).
Benzodiazepines were the most frequently associated drugs, being
prescribed in 111 patients (44.7%).
The majority of JME patients had presented myoclonic and
GTCS at the moment of evaluation (63%), while 35 (28.2%)
presented with myoclonic, absences and GTCS and 11 (8.8%) with
myoclonic and absence seizures. Ninety-one patients (73.3%) were
taking only one AED at the time of the study, and themost common
was valproate (VPA) in 62 patients, followed by topiramate (TPM)
in 19 and phenobarbital (PB) in 10. Of the 33 patients using more
than one AED, 19 were taking VPA and clonazepam (CNZ); 8 TPM
and CNZ and, ﬁnally, 6 VPA and TPM. Sixty-eight had been free of
GTCS for more than 1 year, and 58 had been treated with their
present medications for more than 2 years. Clinical and
demographic data are summarized in Table 1.
PD were found in 100 patients (41%) with MTS. Mood disorders
were the most frequent, being diagnosed in 59 (23.7%). Amongmyoclonic epilepsy.
Juvenile myoclonic epilepsy Statistical test p value
29.813.2 Z=1.1 0.26
72 (58) x2 =0.1 0.35
12.46.5 Z=1.7 0.31
22.59.5 Z=1.4 0.19
73 (58.8) x2 =32.8 0.006*
58 (46.7) x2 =0.1 0.22
72 x2 =1.8 0.12
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dysthymia and 2 with type I bipolar disorder. Thirty-four patients
(13.7%) presented anxiety disorders. Among them, 31 patients
presented generalized anxiety disorder (GAD), 2 social phobia and
1 obsessive-compulsive disorder. Psychotic disorders were seen in
29 patients (11.6%), being IIP in 16 (6.4%) and PIP in 13 (5.2%). There
were also 12 patients (9.6%) with somatoform disorders, all of
them being conversive disorders (non-epileptic events). Thirty-
four patients fulﬁlled criteria for two axis I disorders, 18 of them
presenting major depression and GAD, 9 major depression and
somatoform disorders and 7 major depression and PIP.
Fifty-eight JME patients had presented a PD (46.7%). Mood and
anxiety disorders, present in 31 (25%) and 26 (21%), respectively,
were the most frequently observed. Among mood disorders we
found 26 cases of major depression and 5 of dysthymia, while
among anxiety disorders, 22 presented GAD, 3 speciﬁc phobias and
1 obsessive-compulsive disorder, while among. There were also 7
cases of somatoform disorders, 6 of them conversive disorders
(non-epileptic events) and 1 of somatization, 6 of psychotic
disorders and 2 of alcohol abuse. Fourteen patients fulﬁlled criteria
for two axis I diagnoses. Comparing the two groups, we did not ﬁnd
any statistically signiﬁcant difference in the number of patients
with PD, as well as in the total number of psychiatric diagnoses.
There were also no signiﬁcant differences between the groups
when the number of patients with mood, anxiety or somatoform
disorders was compared. Psychotic disorders, as a group and
separately, were signiﬁcantly related to TLE-MTS group (p = 0.01).
The psychiatric diagnoses are described in Fig. 1.
A comparison of clinical data regarding the presence of PD and
clinical and socio-demographical characteristics was also per-
formed. Thiswas done analyzing the presence of PD (as a group and
individually) and the clinical and socio-demographical variables.
All comparisons were made through an application of an adequate
statistical test (chi-square, Z test or Fisher’s exact test). In TLE-MTS
group, the lateralization of MTS was not related to any psychiatric
diagnose. In addition, no correlationwas observed between seizure
frequency, secondary generalization, the presence of an IPI, or
number and type of AED and the PD. In JME, mood disorders and
GAD were related to inadequate seizure control (p = 0.02). The
presence of treatment with VPA for more than 2 years appeared as
a protecting factor against PD (p = 0.01). There was no association
between duration of epilepsy, type of seizures or time without
treatment to any speciﬁc PD or to a higher frequency of PD in JME
group.[()TD$FIG]
Fig. 1. Psychiatric disorders in mesial temporal sclerosis and in juvenile myoclonic
epilepsy.4. Discussion
The aim of this study was to conduct an evaluation of the
frequency and types of axis I PD in two homogeneous series of
speciﬁc epilepsy syndromes with different pathophysiology and
clinical manifestations: a focal (TLE-MTS) and a primary general-
ized (JME) type. We also aimed to verify possible differences in the
prevalence of PD between these groups and conﬁrm the results of
our previous studywhichwas performedwith a smaller number of
patients.19 Statistical correlations of PD and socio-demographical
and clinical variables such as seizure frequency, type and number
of AED and duration of epilepsy in each group, as well as the
laterality of MTS in TLE, were performed.
Accurate estimates of psychiatric comorbidity in patients with
epilepsy are not easy to ﬁnd, because of the large variety of factors
involved in this type of research, such as type of the study, severity
and chronicity of epilepsy, the methodology applied, the popula-
tion setting and the psychosocial aspects involved in this very
stigmatized disease.1,2,14 This variability could be in part
responsible for the difﬁculty to ﬁnd truly homogeneous patient
groups and adequate controls in literature.25 Although carried out
in a tertiary center, where more patients with refractory epilepsies
are treated, in this study we present two homogeneous groups
paired according to age, gender, duration of epilepsy and age at
epilepsy onset, evaluated through the use of standardized
instruments based on the modern psychiatric nosography.
About 6% of epileptic patients in general appear to suffer from a
PD. This number can rise to 20–40% in populations with TLE and to
70% in populations of refractory epilepsy.1,2 Among these, mood
disorders, particularly depression, are themost common (24–74%),
followed by anxiety disorders (10–25%), psychoses (2–9%) and
personality disorders (1–2%). Although the importance of the
localization of epileptic discharges and the anatomical lesions
provoked by the disease in the development of PD remains unclear,
there is strong evidence that epilepsy places the patient at an
increased risk of developing PD, and adequate controlled studies
existing in literature show a higher risk compared to healthy
control groups.13,25–27 In this study, we found high rates of PD in
both groups andmainly of mood and anxiety disorders, conﬁrming
the high comorbidity of these PD in epilepsy.3,13–18,28We could not
evaluate the prevalence of attention-deﬁcit disorder (ADD), an
entity possibly frequent among epilepsy patients but not covered
by the diagnostic instrument used (SCID-I); this was a limitation of
our study.29
There was no statistically signiﬁcant difference between the
two groups regarding the number of patients diagnosedwith PD or
the total number of psychiatric diagnoses performed. Previous
studies have traditionally highlighted the association between TLE
and PD.6–9,24,28 Limbic involvement has been suggested as a
possible explanation for its high frequency given the role of these
structures in the regulation of emotions and behavior.1–3,6 Other
studies, however, failed to document this association, referring
that TLE per se can not be considered a risk factor in developing
more psychopathology among epilepsy patients and highlighting
the importance of other concomitant factors, such as duration of
epilepsy, seizure frequency and particularly frontal lobe dysfunc-
tions.11–13,25 These results conﬁrm our observations in a previous
study, in which we did not observe such differences.19
A signiﬁcant statistical association of MTS to psychotic
disorders (p < 0.01) was observed in this study. Previous reports
of psychosis have already pointed out a close relation between
those disorders and TLE,30–33 but since psychoses associated to
epilepsy cannot be deﬁned as a single or simple condition but as a
complex entity with several possible subcategories, probably the
disease contributes in different ways to the development of
psychotic states.28,29,33–35 The laterality of the epileptogenic zone
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TLE,25 and the majority of the studies implicates the left
hemisphere12,33–35 or report no effect of lateralization.10 Although
frequently observed among TLE patients, psychotic disorders have
rarely been mentioned in studies of JME using non-subjective
modern rating scales.15–18
In our previous study, a signiﬁcant association was observed
between left-sidedMTS and psychosis (p < 0.01), aswell as JME and
anxiety disorders (p < 0.05).19 These statistical associations were
not signiﬁcant in the present study, in which the same statistical
methodology was performed. This difference could be possibly
attributed to thenumber of patients enrolled in thismore recent and
expanded version, in which more TLE-MTS and JME patients were
evaluated. Nevertheless, other observations still remain statistically
signiﬁcant and concordant with data in current literature.15–20
Mood and anxiety disorders were associated to a higher seizure
frequency in JME group (p = 0.02). Seizure control and compliance
to the treatment are well recognized as very important for the
mental health of these patients,36–38 and some studies have
already suggested a positive correlation between high seizure
frequency and occurrence of psychiatric symptoms in generalized
epilepsies37,38 and in JME, in which such PD and other behavioral
abnormalities could be a constituent of JME or be present in more
serious forms of this syndrome.15–20 Although JME has been
considered a benign condition with good response to antiepileptic
treatment,37,38 there was a high proportion of JME patients who
were not free of GTCS for at least 1 year (45.1%) at the time of the
study, and this could possibly lead to a higher frequency of PD in
this group. Previous treatment with VPA for more than 2 years
appeared as a protecting factor against PD (p = 0.01). This ﬁnding
could be due to a more efﬁcacious seizure control or because of the
well-known therapeutic effects of VPA in psychiatry, as this drug
has been largely used for treatment of a high number of PD.36
We conclude that there was a high prevalence of PD in patients
withTLE-MTS (41%).Ahighprevalencewasalsoobserved inpatients
with JME (46.7%), a form of idiopathic generalized epilepsy.
Psychosis was signiﬁcantly associated to TLE-MTS (p = 0.01). These
ﬁndings are concordantwith data in current literature regarding the
prevalence of PD in both epilepsy syndromes and conﬁrm our
previous observations,19 suggesting the existence of possible
anatomic substrates for the developing of speciﬁc PD that could
correspond to brain dysfunctions provided by each epileptic
syndrome.16,19–21 Once this question is yet to be properly answered,
continued investigation of the psychiatric comorbidity in epileptic
syndromes is certainly recommended.19,24
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